Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA
Abstract Background Adjuvant therapies are now considered standard care for high-risk melanoma patients. It is urgent to identify reliable biomarkers to select patients at high risk of relapse, who will derive more benefit from adjuvant therapy. Methods Targeted next-generation sequencing using a 43...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-11-01
|
| Col·lecció: | BMC Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12885-025-15093-w |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
